Eicosapentaenoic Acid
(Synonyms: 二十碳五烯酸; EPA; Timnodonic acid) 目录号 : GC11344
Eicosapentaenoic Acid（EPA）二十碳五烯酸是一种具有口服活性的omega-3（ω-3）长链多不饱和脂肪酸（PUFA），是前列腺素3、血栓素3和白三烯5类二十烷酸的前体。
Cas No.:10417-94-4
Sample solution is provided at 25 µL, 10mM.
Eicosapentaenoic Acid (EPA) is an orally active omega-3 (ω-3) long-chain polyunsaturated fatty acid (PUFA) and a precursor to prostaglandin-3, thromboxane-3, and leukotriene-5 eicosanoids[1]. Eicosapentaenoic Acid has anti-inflammatory, anti-cardiovascular disease, and anti-diabetic effects. It is found in large quantities in marine organisms[2, 3].
In vitro, Eicosapentaenoic Acid (100 µM) significantly reduces the level of the inflammatory cytokine IL-8 in MDA-MB-231 and MCF-7 breast cancer cells after 48 hours of treatment [4]. Eicosapentaenoic Acid (0.1 μM, 1 μM, 10 μM) induces apoptosis in a dose-dependent manner and activates caspase-3, -7, -9, and PARP enzymes in TE11 and KYSE180 esophageal cancer cells after 24 hours of treatment [5]. Eicosapentaenoic Acid (25 μM) significantly inhibits the proliferation of HT-29 colon cancer cells and downregulates the PI-3K/Akt/mTOR signaling pathway after 24 hours of treatment [6].
In vivo, Eicosapentaenoic Acid (500 mg/kg) administered orally to type 2 diabetic Goto-Kakizaki rats for 4 weeks, significantly reduces circulating insulin levels by 48%, and increases GLUT4 mRNA content in skeletal muscle and adipose tissue [7].
References:
[1] Mason R P, Libby P, Bhatt D L. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid[J]. Arteriosclerosis, thrombosis, and vascular biology, 2020, 40(5): 1135-1147.
[2] Šimat V, Elabed N, Kulawik P, et al. Recent advances in marine-based nutraceuticals and their health benefits[J]. Marine drugs, 2020, 18(12): 627.
[3] Nobre M E P, Correia A O, de Brito Borges M, et al. Eicosapentaenoic acid and docosahexaenoic acid exert anti-inflammatory and antinociceptive effects in rodents at low doses[J]. Nutrition research, 2013, 33(5): 422-433.
[4] Rasha F, Kahathuduwa C, Ramalingam L, et al. Combined effects of eicosapentaenoic acid and adipocyte renin–angiotensin system inhibition on breast cancer cell inflammation and migration[J]. Cancers, 2020, 12(1): 220.
[5] Mizoguchi K, Ishiguro H, Kimura M, et al. Induction of apoptosis by eicosapentaenoic acid in esophageal squamous cell carcinoma[J]. Anticancer research, 2014, 34(12): 7145-7149.
[6] Tang F Y, Cho H J, Pai M H, et al. Concomitant supplementation of lycopene and eicosapentaenoic acid inhibits the proliferation of human colon cancer cells[J]. The Journal of nutritional biochemistry, 2009, 20(6): 426-434.
[7] Figueras M, Olivan M, Busquets S, et al. Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status[J]. Obesity, 2011, 19(2): 362-369.
Eicosapentaenoic Acid（EPA）二十碳五烯酸是一种具有口服活性的omega-3（ω-3）长链多不饱和脂肪酸（PUFA），是前列腺素3、血栓素3和白三烯5类二十烷酸的前体[1]。Eicosapentaenoic Acid具有抗炎、抗心血管疾病、抗糖尿病等作用，在海洋生物中大量存在[2, 3]。
在体外，Eicosapentaenoic Acid（100 µM）处理乳腺癌MDA-MB-231和MCF-7细胞48h，显著降低了细胞内炎症因子IL-8水平[4]。Eicosapentaenoic Acid（0.1 μM、1 μM、10 μM）处理食管癌TE11和KYSE180细胞24h，以剂量依赖性方式诱导细胞凋亡，激活半胱天冬酶-3、-7、-9和PARP酶[5]。Eicosapentaenoic Acid（25μM）处理结肠癌HT-29细胞24h，显著抑制细胞增殖，下调了PI-3K/Akt/mTOR信号通路[6]。
在体内，Eicosapentaenoic Acid（500 mg/kg）通过口服治疗2型糖尿病Goto-Kakizaki大鼠4周，显著减少了循环胰岛素（48%），还导致骨骼肌和脂肪组织中的GLUT4 mRNA含量增加[7]。
| Cell experiment [1]: | |
Cell lines | MDA-MB-231、MCF-7 cells |
Preparation Method | MDA-MB-231 and MCF-7 cells were treated with 100 µM of Eicosapentaenoic Acid for 48 h. |
Reaction Conditions | 100 µM; 48h |
Applications | Eicosapentaenoic Acid treatment significantly reduced the level of IL-8 in cells. |
| Animal experiment [2]: | |
Animal models | Male 3-week-old Goto-Kakizaki rats |
Preparation Method | Male 3-week-old Goto-Kakizaki rats were used. This is a rat model with spontaneous type 2 diabetes. The animals were maintained on a regular light-dark cycle at an ambient temperature and had free access to food and water. Rats were divided into one of three groups: control, Eicosapentaenoic Acid (EPA) and linoleic acid (LINO), respectively. EPA group: animals fed the same as control but supplemented daily with 500mg/kg body weight of EPA mixed in carboxymethylcellulose 1% given by a single gavage. The treatment took place for 4 weeks before the animals were killed. |
Dosage form | 500mg/kg; p.o. |
Applications | Administration of Eicosapentaenoic Acid resulted in a significant decrease in circulating insulin (48%), this was not observed in the LINO group. Eicosapentaenoic Acid resulted in an increased GLUT4 mRNA content in both skeletal muscle and adipose tissue. |
References: | |
| Cas No. | 10417-94-4 | SDF | |
| 别名 | 二十碳五烯酸; EPA; Timnodonic acid | ||
| 化学名 | (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid | ||
| Canonical SMILES | CC/C([H])=C([H])\C/C([H])=C([H])\C/C([H])=C([H])\C/C([H])=C([H])\C/C([H])=C([H])\CCCC(O)=O | ||
| 分子式 | C20H30O2 | 分子量 | 302.45 |
| 溶解度 | ≥ 116.8mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3063 mL | 16.5317 mL | 33.0633 mL |
| 5 mM | 0.6613 mL | 3.3063 mL | 6.6127 mL |
| 10 mM | 0.3306 mL | 1.6532 mL | 3.3063 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet